"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Descriptor ID |
D018719
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
|
Concept/Terms |
Receptor, ErbB-2- Receptor, ErbB-2
- ErbB-2 Receptor
- Antigens, CD340
- CD340 Antigens
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- p185(c-neu)
- c-erbB-2 Protein
- c erbB 2 Protein
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Receptors, erbB-2
- erbB-2 Receptors
- Neu Receptor
- Receptor, Neu
- Metastatic Lymph Node Gene 19 Protein
- Proto-oncogene Protein Neu
- Neu, Proto-oncogene Protein
- Proto-oncogene c-ErbB-2
- c-ErbB-2, Proto-oncogene
- Tyrosine Kinase-type Cell Surface Receptor HER2
- Tyrosine Kinase type Cell Surface Receptor HER2
- p185erbB2 Protein
- CD340 Antigen
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-2 [D12.776.543.750.630.009.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Receptor, ErbB-2 [D23.050.301.500.600.700]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Receptor, ErbB-2 [D23.050.705.552.600.550]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-2 [D23.101.140.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".
This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 12 | 15 |
1995 | 5 | 1 | 6 |
1996 | 5 | 5 | 10 |
1997 | 11 | 4 | 15 |
1998 | 13 | 3 | 16 |
1999 | 12 | 6 | 18 |
2000 | 19 | 3 | 22 |
2001 | 16 | 5 | 21 |
2002 | 6 | 7 | 13 |
2003 | 19 | 8 | 27 |
2004 | 29 | 8 | 37 |
2005 | 22 | 20 | 42 |
2006 | 22 | 15 | 37 |
2007 | 27 | 24 | 51 |
2008 | 22 | 15 | 37 |
2009 | 27 | 23 | 50 |
2010 | 29 | 29 | 58 |
2011 | 38 | 32 | 70 |
2012 | 33 | 33 | 66 |
2013 | 26 | 33 | 59 |
2014 | 20 | 24 | 44 |
2015 | 30 | 18 | 48 |
2016 | 23 | 27 | 50 |
2017 | 20 | 38 | 58 |
2018 | 25 | 24 | 49 |
2019 | 36 | 13 | 49 |
2020 | 17 | 28 | 45 |
2021 | 23 | 38 | 61 |
2022 | 5 | 31 | 36 |
2023 | 1 | 52 | 53 |
2024 | 2 | 13 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clin Cancer Res. 2024 Apr 01; 30(7):1273-1280.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720.
-
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024 Apr; 201:113920.
-
ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 May; 31(5):3196-3197.
-
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression. Arch Pathol Lab Med. 2024 Feb 01; 148(2):242-255.